Management of the adverse effects of lenalidomide in multiple myeloma
Abstract The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival. On the other hand, when new drugs are used it is very important to know their associated toxicity, since adequate management of the adverse effects can help to avoid unnecessary treatment interruptions — thereby undoubtedly contributing to improvement in the efficacy of therapy. The present study reviews the main hematological and nonhematological adverse effects potentially associated with the use of lenalidomide in its most common combinations used for the treatment of multiple myeloma, and the recommendations for dealing with such effects..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Advances in therapy - 28(2011), Suppl 1 vom: 09. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rodríguez, Ana Pilar González [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Springer Healthcare 2011 |
---|
doi: |
10.1007/s12325-010-0104-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR024924393 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR024924393 | ||
003 | DE-627 | ||
005 | 20230519153652.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-010-0104-8 |2 doi | |
035 | |a (DE-627)SPR024924393 | ||
035 | |a (SPR)s12325-010-0104-8-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rodríguez, Ana Pilar González |e verfasserin |4 aut | |
245 | 1 | 0 | |a Management of the adverse effects of lenalidomide in multiple myeloma |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Healthcare 2011 | ||
520 | |a Abstract The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival. On the other hand, when new drugs are used it is very important to know their associated toxicity, since adequate management of the adverse effects can help to avoid unnecessary treatment interruptions — thereby undoubtedly contributing to improvement in the efficacy of therapy. The present study reviews the main hematological and nonhematological adverse effects potentially associated with the use of lenalidomide in its most common combinations used for the treatment of multiple myeloma, and the recommendations for dealing with such effects. | ||
650 | 4 | |a adverse effects |7 (dpeaa)DE-He213 | |
650 | 4 | |a lenalidomide |7 (dpeaa)DE-He213 | |
650 | 4 | |a multiple myeloma |7 (dpeaa)DE-He213 | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 28(2011), Suppl 1 vom: 09. März |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2011 |g number:Suppl 1 |g day:09 |g month:03 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-010-0104-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 28 |j 2011 |e Suppl 1 |b 09 |c 03 |